Citing Shortages Tied To COVID-19, FDA Allows Some Alternative Flu Test Materials
The agency won’t require a 510(k) if manufacturers make some substitutions for materials now in high demand for COVID-19 tests.
You may also be interested in...
FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.
The US Court of Appeals for the Ninth Circuit found that Sensory NeuroStimulation Inc., which makes a device to treat restless leg syndrome, hadn’t exhausted all administrative remedies.
Investors in surgical robotics company Auris say Johnson & Johnson failed to support the company per their merger agreement.